FDA Approves First OTC Tylenol with Naproxen for 12-Hour Pain Relief

The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen (acetaminophen 325 mg / naproxen sodium 110 mg tablets) as the first and only nonprescription, fixed-dose combination of acetaminophen and naproxen sodium. Approved on July 24, the product is indicated for the temporary relief of minor aches and pains including headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain in adults and children aged 12 years and older.

The approval introduces a new over the counter (OTC) multimodal analgesic option that combines the rapid onset of acetaminophen with the prolonged anti-inflammatory and analgesic activity of naproxen sodium in a single tablet. Patients take two tablets every 12 hours, delivering a total dose of 650 mg acetaminophen and 220 mg naproxen sodium for sustained pain relief.

Combining Two Established Analgesics in One OTC Product

Acetaminophen has long served as a first-line analgesic and antipyretic, while naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting cyclooxygenase-mediated prostaglandin synthesis. Although OTC products combining acetaminophen with other NSAIDs already exist, this is the first FDA-approved nonprescription product to pair acetaminophen with naproxen sodium in a fixed-dose tablet.

The FDA noted that the approval supports broader access to verified nonprescription medicines, aligning with federal efforts to expand consumer access to safe OTC therapies while reducing reliance on healthcare visits for common, self-treatable conditions.

Eight Clinical Studies Supported FDA Approval

The approval was supported by eight clinical studies demonstrating that the fixed-dose combination provided greater pain relief than either acetaminophen alone or naproxen sodium 220 mg alone (Aleve). Clinical data also showed:

• Onset of pain relief in under 30 minutes
• Sustained analgesia lasting up to 12 hours after a single dose
• Meaningful contributions from each active ingredient toward the overall therapeutic effect

According to manufacturer Kenvue, additional findings from the clinical development program will be presented at PAINWeek 2026.

Safety Profile Reflects Established Acetaminophen and NSAID Risks

The product labeling incorporates standard warnings associated with both active ingredients:

Acetaminophen Risk: Consumers should avoid taking Tylenol with Naproxen alongside other acetaminophen-containing products, as excessive cumulative doses can cause severe liver injury.

NSAID Risk: The naproxen sodium component carries established NSAID warnings for gastrointestinal bleeding and an increased risk of heart attack, heart failure, and stroke, particularly when used above the recommended dose or for prolonged periods.

Pregnancy & Breastfeeding: The product label advises pregnant or breastfeeding individuals to consult a healthcare professional before use. Consistent with existing NSAID recommendations, the product should not be used at 20 weeks of pregnancy or later unless specifically directed by a physician.

Industry Commentary & Commercial Significance

Manufacturer Kenvue Brands LLC was granted three years of marketing exclusivity by the FDA for the novel OTC formulation.

“The approval offers consumers a simplified, opioid-free option that combines rapid onset with prolonged pain relief in a single product,” stated Dr. Rajesh Mishra, Chief Medical Officer at Kenvue.

Principal investigator Dr. Todd Bertoch added that the extensive clinical program demonstrated both the efficacy of the fixed-dose combination and the practical benefit of eliminating the need for patients to manage and combine separate OTC medicines themselves.

Path Forward

Following FDA approval, Kenvue expects to launch U.S. commercialization of Tylenol with Naproxen under its three-year exclusivity period. The approval expands non-opioid pain management options by introducing the first fixed-dose acetaminophen and naproxen sodium combination available without a prescription, providing a simplified twice-daily regimen for common pain conditions. please review this version i have made slight changes like added investigator before Dr. Todd statement 

Reference

FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief | FDA

FDA approves Tylenol® with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg) – A new view of care